CAMBRIDGE, Mass., Jan. 10, 2020 – Generation Bio, a company leading a new generation of gene therapy, today announced the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020.
President and Chief Executive Officer Geoff McDonough, M.D., will provide an overview of the company’s progress and anticipated milestones for 2020.
Generation Bio’s non-viral platform moves beyond the limitations of existing gene therapy by enabling re-dosable long-lasting gene therapies for severe diseases on a global scale. The platform combines three unique technologies: a novel cell-targeted lipid nanoparticle delivery system (ctLNP), a proprietary closed-ended DNA construct (ceDNA) and a high-capacity capsid-free biologics manufacturing process. The company recently announced a $110 million Series C financing to support the advancement of its two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU) into IND-enabling studies.
Date: Tuesday, January 14, 2020
Time: 10:00 a.m. PT
Location: Westin St. Francis Hotel, Elizabethan D
About Generation Bio
Generation Bio is a biotechnology company leading a new generation of re-dosable long-lasting gene therapy on a scale to potentially benefit more families living with a broader range of diseases around the world. The company’s powerful non-viral platform combines three unique technologies: a novel cell-targeted lipid nanoparticle delivery system (ctLNP), a proprietary closed-ended DNA construct (ceDNA) and a high-capacity capsid-free biologics manufacturing process. In addition to its lead liver-targeted programs in hemophilia A and phenylketonuria (PKU), Generation Bio is developing gene therapies for patients with diseases of skeletal muscle and the eye. Generation Bio was founded by Atlas Venture and is headquartered in Cambridge, Mass.
Ten Bridge Communications